Vaxil’s lead product ImMucin binds to multiple human MHC Class I and Class II alleles and B cell epitopes. This characteristic allows a broad and robust cellular anti-tumor immunity by activating multiple CD4+ and CD8+ T-cell clones and antibody-dependent cell-mediated cytotoxicity (ADCC). This combination of T and B -cell response is important for any anti-MUC1 vaccine.
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.